JP2010527981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527981A5 JP2010527981A5 JP2010508909A JP2010508909A JP2010527981A5 JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5 JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5
- Authority
- JP
- Japan
- Prior art keywords
- week
- chk
- administered
- treatment
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94020307P | 2007-05-25 | 2007-05-25 | |
| PCT/GB2008/050372 WO2008146035A1 (en) | 2007-05-25 | 2008-05-23 | Combination of chk and parp inhibitors for the treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527981A JP2010527981A (ja) | 2010-08-19 |
| JP2010527981A5 true JP2010527981A5 (https=) | 2011-06-30 |
Family
ID=39672970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508909A Pending JP2010527981A (ja) | 2007-05-25 | 2008-05-23 | 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100249112A1 (https=) |
| EP (1) | EP2167086A1 (https=) |
| JP (1) | JP2010527981A (https=) |
| KR (1) | KR20100020981A (https=) |
| CN (1) | CN101743003A (https=) |
| AU (1) | AU2008256562A1 (https=) |
| BR (1) | BRPI0811059A2 (https=) |
| CA (1) | CA2687786A1 (https=) |
| MX (1) | MX2009012705A (https=) |
| RU (1) | RU2009147819A (https=) |
| WO (1) | WO2008146035A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081778A1 (en) * | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| PL2938598T3 (pl) | 2012-12-31 | 2017-05-31 | Cadila Healthcare Limited | Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy) |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3609884A4 (en) | 2017-04-10 | 2021-01-06 | Sierra Oncology, Inc. | CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| CA3095709A1 (en) | 2018-04-05 | 2019-10-10 | Noviga Research Ab | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| WO2022000946A1 (zh) * | 2020-06-29 | 2022-01-06 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN112375070B (zh) * | 2020-06-29 | 2023-03-28 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| KR20260030809A (ko) | 2023-06-21 | 2026-03-06 | 테트라곤 바이오사이언시스 엘티디 | Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0408284B8 (pt) * | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| KR20060123403A (ko) * | 2003-12-01 | 2006-12-01 | 쿠도스 파마슈티칼스 리미티드 | 암 치료를 위한 ｄｎａ 손상 수복 억제제 |
| BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| EP1836320A2 (en) * | 2005-01-07 | 2007-09-26 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
| WO2008020180A2 (en) * | 2006-08-17 | 2008-02-21 | Kudos Pharmaceuticals Limited | Methods of increasing the sensitivity of cancer cells to dna damage |
-
2008
- 2008-05-23 CN CN200880024432A patent/CN101743003A/zh active Pending
- 2008-05-23 US US12/601,328 patent/US20100249112A1/en not_active Abandoned
- 2008-05-23 CA CA2687786A patent/CA2687786A1/en not_active Abandoned
- 2008-05-23 BR BRPI0811059A patent/BRPI0811059A2/pt not_active IP Right Cessation
- 2008-05-23 WO PCT/GB2008/050372 patent/WO2008146035A1/en not_active Ceased
- 2008-05-23 JP JP2010508909A patent/JP2010527981A/ja active Pending
- 2008-05-23 KR KR1020097026995A patent/KR20100020981A/ko not_active Withdrawn
- 2008-05-23 MX MX2009012705A patent/MX2009012705A/es unknown
- 2008-05-23 RU RU2009147819/15A patent/RU2009147819A/ru not_active Application Discontinuation
- 2008-05-23 EP EP08750767A patent/EP2167086A1/en not_active Withdrawn
- 2008-05-23 AU AU2008256562A patent/AU2008256562A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010527981A5 (https=) | ||
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| JP2013507415A5 (https=) | ||
| FI4303583T3 (fi) | Csf1r-estäjiä käytettäviksi tenosynoviaalisen jättisolukasvaimien hoidossa | |
| FI2694072T4 (fi) | Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa | |
| JP2014515373A5 (https=) | ||
| EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2014528901A5 (https=) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2012526850A5 (https=) | ||
| JP2016508134A5 (https=) | ||
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| JP2016529285A5 (https=) | ||
| EP4520398A3 (en) | Treatment of prostate cancer | |
| UA104148C2 (ru) | [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток | |
| JP2015527374A5 (https=) | ||
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| JP2013544892A5 (https=) | ||
| IL259512B1 (en) | Combination for effective treatment of metastatic cancer in patients | |
| JP2008534503A5 (https=) |